• 한국수자원학회:학술대회논문집
• /
• 한국수자원학회 2005년도 학술발표회(1)
• /
• pp.253-254
• /
• 2005

• 한국식물생명공학회:학술대회논문집
• /
• 한국식물생명공학회 2005년도 추계학술대회 및 한일 식물생명공학 심포지엄
• /
• pp.345-345
• /
• 2005

• Bulletin of the Korean Chemical Society
• /
• 제33권11호
• /
• pp.3857-3860
• /
• 2012

• Bulletin of the Korean Chemical Society
• /
• 제31권4호
• /
• pp.1085-1087
• /
• 2010

• 대한약학회:학술대회논문집
• /
• 대한약학회 2000년도 NEW STRATEGY FOR DRUG DEVELOPMENT IN POST-GENOMIC ERA(대한약학회)
• /
• pp.211.3-212
• /
• 2000

• Archives of Pharmacal Research
• /
• 제18권3호
• /
• pp.206-212
• /
• 1995

New hypolipaemic agents, in which substituted indazole nucleus is connected to tetrahydro-4-hydroxy-2H-pyran-2-one by a two-carbon bridge, were designed and synthesized to show significant inhibitory activity against microsomal HMG-CoA reductase in rat liver.

• 대한환경공학회지
• /
• 제39권3호
• /
• pp.124-131
• /
• 2017

생물활성탄 공정과 안트라사이트를 여재로 사용한 biofilter에서 공탑 체류시간(EBCT)과 수온의 변화에 따른 8종의 고지혈증 치료제류(blood lipid regulator agents, BLLAs)의 생물분해 특성을 평가하였다. 수온 $8^{\circ}C$, $16^{\circ}C$ 및 $24^{\circ}C$에서 공탑 체류시간을 5분~15분까지 변화시켰다. 생물활성탄 공정에서 고지혈증 치료제류 8종의 생물분해 제거율은 공탑 체류시간과 수온의 변화에 많은 영향을 받았으며, 공탑 체류시간과 수온이 증가할수록 생분해 제거율이 증가하였다. 고지혈증 치료제류의 종류에 따른 생물활성탄 공정에서 생분해 제거율은 statin계의 경우 simvastatin이 가장 높았으며 다음으로 mevastatin, fluvastatin 및 atorvastatin 순이었다. 또한, Fibrate계 고지혈증 치료제들의 생물분해능은 fenofibrate가 가장 높았으며 다음으로 gemfibrozil, bezafibrate, clofibric acid순이었다. BAC 공정에서 생물분해 제거능이 가장 낮은 clofibric acid와 atorvastatin의 생물분해 속도상수($k_{bio}$)는 수온이 $8^{\circ}C$에서 $24^{\circ}C$로 상승하였을 경우, 각각 $0.0075min^{-1}$과 $0.0122min^{-1}$에서 $0.0540min^{-1}$과 $0.0866min^{-1}$으로 증가하여 각각 7.2배 및 7.1배 정도 증가하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권12호
• /
• pp.5087-5094
• /
• 2016

mTOR, the mammalian target of rapamycin, is a conserved serine/threonine kinase which belongs to the phosphatidyl-linositol kinase-related kinase (PIKK) family. It has two complexes called mTORC1 and mTORC2. It is well established that mTOR plays important roles in cell growth, proliferation and differentiation. Over-activation of the mTOR pathway is considered to have a relationship with the development of many types of diseases, including polycystic ovary syndrome (PCOS) and ovarian cancer (OC). mTOR pathway inhibitors, such as rapamycin and its derivatives, can directly or indirectly treat or relieve the symptoms of patients suffering from PCOS or OC. Moreover, mTOR inhibitors in combination with other chemical-molecular agents may have extraordinary efficacy. This paper will discuss links between mTOR signaling and PCOS and OC, and explore the mechanisms of mTOR inhibitors in treating these two diseases, with conclusions regarding the most effective therapeutic approaches.

• Journal of Microbiology
• /
• 제41권3호
• /
• pp.252-258
• /
• 2003

The carbon utilizations of Bacillus species and Pythium species were investigated by using a Biolog$^{(R)}$ microplate assay to determine if there are differences in the carbon utilizations of selected strains of these species. It may be possible to afford a competitive advantage to bacterial biological control agents by providing them with a substrate that they can readily use as a carbon source, for example, in a seed coating formulation. Microplates, identified as SFP, SFN and YT were used to identify spore-forming bacteria, nonspore-forming bacteria, and yeast, respectively. Bacterial and mycelial suspensions were adjusted to turbidities of 0.10 to 0.11 at 600 nm. One hundred microliters of each of the bacterial and mycelial suspension were inoculated into each well of each of the three types of microplates. L-arabinose, D-galactose, D-melezitose and D-melibiose of the 147 carbohydrates tested were found to be utilized only by bacteria, and not by Pythium species, by Biolog$^{(R)}$ microplate assay, and this was confirmed by traditional shake flask culture. Thus, it indicated that the Biolog$^{(R)}$ microplate assay could be readily used to search for specific carbon sources that could be utilized to increase the abilities of bacterial biological control agents to adapt to contrived environments.

• 생물정신의학
• /
• 제6권1호
• /
• pp.49-66
• /
• 1999

Polypharmacotherapy, both psychotropic and nonpsychotropic, is widespread in various situations including psychiatric hospitals and general hospitals. As the clinical practice of using more than one drug at a time increase, the clinician is faced with ever-increasing number of potential drug interactions. Although many interactions have little clinical significances, some may interfere with treatment or even be life-threatening. The objective of this review is evaluation for drug-drug interactions often encountered in psychiatric consultation. Drug interactions can be grouped into two principal subdivisions : pharmacokinetic and pharmacodynamic. These subgroups serve to focus attention on possible sites of interaction as a drug moves from the site of administration and absorption to its site of action. Pharmacokinetic processes are those that include transport to and from the receptor site and consist of absorption, distribution on body tissue, plasma protein binding, metabolism, and excretion. Pharmacodynamic interactions occur at biologically active sites. In psychiatric consultation, these two subdivisions of drug interactions between psychotropic drugs and other drugs are likely to happen. We gathered informations of the drugs used in physically ill patients who are consulted to psychiatric department in Korea University Hospital. And we reviewed the related literatures about the drug-drug interactions between psychotropic drugs and other drugs.